Latest News Archive

Please select Category, Year, and then Month to display items
Categories
UFS News Media Release Research
Years
2017 2018 2019 2020 2021 2022 2023 2024
Months
January February March April May June July August September October November December
Previous Archive
16 April 2020 | Story Department of Communication and Marketing | Photo Charl Devenish
Farmovs
In 2019, FARMOVS was pre-qualified by the WHO to support clinical studies aimed at improving access to quality generic medicines across the globe.
The University of the Free State (UFS) is committed to supporting government’s efforts to overcome the COVID-19 pandemic. During this challenging time, dedicated staff members at the UFS continue to provide services as a testimony to their commitment to advance public knowledge of COVID-19 for the greater good of South Africa.

The following is a synopsis of the areas in which the UFS is actively assisting.

Public Health Emergency Solidarity Trial
Clinicians from the Department of Internal Medicine, the Department of Critical Care, and the Division of Virology will be working with FARMOVS to participate in the Public Health Emergency Solidarity Trial initiated by the World Health Organization (WHO). This international randomised trial will evaluate four treatment options (remdesivir, lopinavir/ritonavir, lopinavir/ritonavir plus interferon, chloroquine or hydroxychloroquine) for the treatment of COVID-19. 

The trial is expected to include more than 45 countries worldwide, including a number of South African sites. 

Farmovs
FARMOVS is in a planning process to support all the Bloemfontein hospitals, including Pelonomi, Universitas, 3 Military Hospital, Mediclinic, and Rosepark, in conducting the largest global trial on COVID-19 – the Public Health Emergency Solidarity Trial, under leadership of the WHO.   

Negotiations are ongoing between the UFS and the Department of Health in the Free State for FARMOVS to offer support with the continuation of healthcare to non-COVID-19 patients in an attempt to free up space at Universitas Hospital for isolation of COVID-19 patients. 

In 2019, FARMOVS was pre-qualified by the WHO to support clinical studies aimed at improving access to quality generic medicines across the globe.  FARMOVS also receives feasibility requests for support with the evaluation of existing drugs (repurposing) as well as the development of novel drugs for the treatment of COVID-19 – this is an ongoing process.

Disaster Management Training and Education Centre (DiMTEC)
DiMTEC represents the UFS on the Provincial Joint Operation Centre (PROVJOC). The PROVJOC is a fully equipped, dedicated facility that is proactively established to enable all relevant role players /disciplines to jointly manage all safety and security-related aspects of any planned event or any major incident which has occurred or is imminent – especially in the response and recovery operations phase – at the strategic and/or tactical level, using the Unified Command System. This facility is also linked to all other established safety and security centres.

Research and Innovation
The UFS hosts a SARChI Research Chair in vector-borne and zoonotic diseases, and recently invested in the establishment of a biosafety level-3 facility. Hence, there is expertise on the campus to plan and conduct research on zoonotic and medically significant viruses. In addition, there are research groups focusing on protein expression systems with potential for utilisation in the development of diagnostic assays with application in either diagnosis or surveillance.

Currently, researchers at the UFS have established several projects that will contribute directly towards the COVID-19 outbreak.


News Archive

Expert in Africa Studies debunks African middle class myth
2016-05-10

Description: Prof Henning Melber Tags: Prof Henning Melber

From left: Prof Heidi Hudson, Director of the Centre for Africa Studies (CAS), Joe Besigye from the Institute of Reconciliation and Social Justice, and Prof Henning Melber, Extraordinary Professor at the CAS and guest lecturer for the day.
Photo: Valentino Ndaba

Until recently, think tanks from North America, the African Development Bank, United Nations Development Plan, and global economists have defined the African middle class based purely on monetary arithmetic. One of the claims made in the past is that anyone with a consumption power of $2 per day constitutes the middle class. Following this, if poverty is defined as monetary income below $1.5 a day, it means that it takes just half a dollar to reach the threshold considered as African middle class.

Prof Henning Melber highlighted the disparities in the notion of a growing African middle class in a guest lecture titled A critical anatomy of the African middle class(es), hosted by our Centre for Africa Studies (CAS) at the University of the Free State on 4 May 2016. He is an Extraordinary Professor at the Centre, as well as Senior Adviser and Director Emeritus of the Dag Hammarskjöld Foundation in Sweden.

Prof Melber argued that it is misleading to consider only income when identifying the middle class. In his opinion, such views were advanced by promoters of the global neo-liberal project. “My suspicion is that those who promote the middle class  discourse in that way, based on such a low threshold, were desperate to look for the success story that testifies to Africa rising.”

Another pitfall of such a middle-class analysis is its ahistorical contextualisation. This economically-reduced notion of the class is a sheer distortion. Prof Melber advised analysts to take cognisance of factors, such as consumption patterns, lifestyle, and political affiliation, amongst others.

In his second lecture for the day, Prof Melber dealt withthe topic of: Namibia since independence: the limits to Liberation, painting the historical backdrop against which the country’s current government is consolidating its political hegemony. He highlighted examples of the limited transformation that has been achieved since Namibia’s independence in 1990.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept